Megan Dunbar
Research Subjects
Megan Dunbar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Chiedza Gavi
Centre for Sexual Health, HIV/AIDS Research, Harare, Zimbabwe
2 shared publications- Collin Mangenah
Affiliations Centre for Sexual Health and HIV/AIDS Research (CeSHHAR), Harare, Zimbabwe, Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
2 shared publications - Definate Nhamo
Affiliation School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
2 shared publications Emily Gwavava
Pangaea Zimbabwe AIDS Trust (PZAT), Harare, Zimbabwe
2 shared publications- Fern Terris-Prestholt
The Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland
2 shared publications - Frances M. Cowan
International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK
2 shared publications
Latest Publications
- Open Access
- 30 August 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (11) , 1707-1716
Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort
Objectives: To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed‐dose combination 3‐drug and 2‐drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US. Methods: From the OPERA cohort, ART‐experienced, virologically suppressed (viral load 200 ; 2 viral loads ≥200 copies/mL or 1 viral load ≥200 copies/mL + discontinuation) or time to discontinuation. Results: A total of 3512 B/F/TAF users were followed for a median of 16 months (IQR: 11, 22); 2327 DTG/3TC users were followed for a median of 15 months (IQR: 10, 21). cVF 200 was observed among 2% of B/F/TAF and 3% of DTG/FTC users, for an adjusted hazard ratio of 0.84 (95% CI: 0.59, 1.18) for B/F/TAF compared with DTG/3TC. Regimen discontinuation was observed among 17% of B/F/TAF and 19% of DTG/3TC users, for an adjusted hazard ratio of 0.83 (95% CI: 0.73, 0.94) for B/F/TAF compared with DTG/3TC. Treatment‐related reasons for discontinuation represented 6% of B/F/TAF and 9% of DTG/3TC discontinuations. Conclusions: In this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.
- 30 August 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (11) , 1707-1716
Open AccessSuppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort
Objectives: To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed‐dose combination 3‐drug and 2‐drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US. Methods: From the OPERA cohort, ART‐experienced, virologically suppressed (viral load 200 ; 2 viral loads ≥200 copies/mL or 1 viral load ≥200 copies/mL + discontinuation) or time to discontinuation. Results: A total of 3512 B/F/TAF users were followed for a median of 16 months (IQR: 11, 22); 2327 DTG/3TC users were followed for a median of 15 months (IQR: 10, 21). cVF 200 was observed among 2% of B/F/TAF and 3% of DTG/FTC users, for an adjusted hazard ratio of 0.84 (95% CI: 0.59, 1.18) for B/F/TAF compared with DTG/3TC. Regimen discontinuation was observed among 17% of B/F/TAF and 19% of DTG/3TC users, for an adjusted hazard ratio of 0.83 (95% CI: 0.73, 0.94) for B/F/TAF compared with DTG/3TC. Treatment‐related reasons for discontinuation represented 6% of B/F/TAF and 9% of DTG/3TC discontinuations. Conclusions: In this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.
- 5 October 2021
- Published by Springer Nature in AIDS and Behavior
- Vol. 26 (1) , 171
Correction to: Efficiency in PrEP Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe
- 5 October 2021
- Published by Springer Nature in AIDS and Behavior
- Vol. 26 (1) , 171
Correction to: Efficiency in PrEP Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe
- Open Access
- 27 August 2021
- Published by Springer Nature in AIDS and Behavior
- Vol. 26 (1) , 161-170
Efficiency in PrEP Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe
Although oral PrEP is highly effective at preventing HIV acquisition, optimizing continuation among beneficiaries is challenging in many settings. We estimated the costs of delivering oral PrEP to populations at risk of HIV in seven clinics in Zimbabwe. Full annual economic costs of oral PrEP initiations and continuation visits were estimated from the providers’ perspective for a six-clinic NGO network and one government SGBV clinic in Zimbabwe (January–December 2018). Disaggregating costs of full initiation and incremental follow-up visits enabled modeling of the impact of duration of continuation on the cost per person-year ($pPY) on PrEP. 4677 people initiated oral PrEP, averaging 2.7 follow-up visits per person. Average cost per person initiated was $238 ($183–$302 across the NGO clinics; $86 in the government facility). The full cost per initiation visit, including central and direct costs, was $178, and the incremental cost per follow-up visit, capturing only additional resources used directly in the follow up visits, was $22. The average duration of continuation was 3.0 months, generating an average $pPY of $943, ranging from $839 among adolescent girls and young women to $1219 in men. Oral PrEP delivery costs varied substantially by scale of initiations and by duration of continuation and type of clinic. Extending the average oral PrEP continuation from 2.7 to 5 visits (about 6 months) would greatly improve service efficiency, cutting the $pPY by more than half.
- 27 August 2021
- Published by Springer Nature in AIDS and Behavior
- Vol. 26 (1) , 161-170
Open AccessEfficiency in PrEP Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe
Although oral PrEP is highly effective at preventing HIV acquisition, optimizing continuation among beneficiaries is challenging in many settings. We estimated the costs of delivering oral PrEP to populations at risk of HIV in seven clinics in Zimbabwe. Full annual economic costs of oral PrEP initiations and continuation visits were estimated from the providers’ perspective for a six-clinic NGO network and one government SGBV clinic in Zimbabwe (January–December 2018). Disaggregating costs of full initiation and incremental follow-up visits enabled modeling of the impact of duration of continuation on the cost per person-year ($pPY) on PrEP. 4677 people initiated oral PrEP, averaging 2.7 follow-up visits per person. Average cost per person initiated was $238 ($183–$302 across the NGO clinics; $86 in the government facility). The full cost per initiation visit, including central and direct costs, was $178, and the incremental cost per follow-up visit, capturing only additional resources used directly in the follow up visits, was $22. The average duration of continuation was 3.0 months, generating an average $pPY of $943, ranging from $839 among adolescent girls and young women to $1219 in men. Oral PrEP delivery costs varied substantially by scale of initiations and by duration of continuation and type of clinic. Extending the average oral PrEP continuation from 2.7 to 5 visits (about 6 months) would greatly improve service efficiency, cutting the $pPY by more than half.